CY1115420T1 - Δικυκλικες ενωσεις και οι χρησεις τους ως διπλοι αναστολεις c-src/jak - Google Patents

Δικυκλικες ενωσεις και οι χρησεις τους ως διπλοι αναστολεις c-src/jak

Info

Publication number
CY1115420T1
CY1115420T1 CY20141100393T CY141100393T CY1115420T1 CY 1115420 T1 CY1115420 T1 CY 1115420T1 CY 20141100393 T CY20141100393 T CY 20141100393T CY 141100393 T CY141100393 T CY 141100393T CY 1115420 T1 CY1115420 T1 CY 1115420T1
Authority
CY
Cyprus
Prior art keywords
jak
src
compounds
present
kinase inhibitors
Prior art date
Application number
CY20141100393T
Other languages
English (en)
Inventor
Allister Andrès Mc
Maximilien Murone
Saumitra Sengupta
Shankar Jayaram Shetty
Original Assignee
Debiopharm S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm S.A. filed Critical Debiopharm S.A.
Publication of CY1115420T1 publication Critical patent/CY1115420T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε υποκατασταθείσες αρωματικές δικυκλικές ενώσεις περιέχουσες δακτυλίους πυριμιδίνης και πυριδίνης έχουσες τη δομή τύπου (I) καθώς επίσης και σε φαρμακευτικά αποδεκτά άλατα αυτών. Οι ενώσεις της παρούσας εφευρέσεως είναι χρήσιμες ως αναστολείς κινάσης της τυροσίνης, κατά προτίμηση αναστολείς των κινασών της οικογένειας SRC (SFK), συγκεκριμένα ως πολλαπλοί αναστολείς κινασών SFK/JAK και ακόμη προτιμότερα ως διπλοί αναστολείς κινασών c-SRC/JAK, αναστέλλοντας τοιουτοτρόπως την ενεργοποίηση του STAT3 και κατά συνέπεια την αφύσικη ανάπτυξη συγκεκριμένων κυτταρικών τύπων. Αξιοσημείωτα, οι ενώσεις της παρούσας εφευρέσεως είναι χρήσιμες για την αγωγή ή αναστολή ορισμένων νόσων που είναι το αποτέλεσμα της απορυθμίσεως του STAT3.
CY20141100393T 2010-02-17 2014-06-03 Δικυκλικες ενωσεις και οι χρησεις τους ως διπλοι αναστολεις c-src/jak CY1115420T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN415CH2010 2010-02-17
EP11709484.7A EP2536722B1 (en) 2010-02-17 2011-02-17 Bicyclic compounds and their uses as dual c-src / jak inhibitors

Publications (1)

Publication Number Publication Date
CY1115420T1 true CY1115420T1 (el) 2017-01-04

Family

ID=43903941

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100393T CY1115420T1 (el) 2010-02-17 2014-06-03 Δικυκλικες ενωσεις και οι χρησεις τους ως διπλοι αναστολεις c-src/jak

Country Status (28)

Country Link
US (2) US8440679B2 (el)
EP (1) EP2536722B1 (el)
JP (1) JP2013519725A (el)
KR (1) KR20120130294A (el)
CN (1) CN102858770A (el)
AR (1) AR089641A1 (el)
AU (1) AU2011216895B2 (el)
BR (1) BR112012020639A2 (el)
CA (1) CA2789655A1 (el)
CU (1) CU20120118A7 (el)
CY (1) CY1115420T1 (el)
DK (1) DK2536722T3 (el)
EA (1) EA201290757A1 (el)
ES (1) ES2470190T3 (el)
HK (1) HK1178897A1 (el)
HR (1) HRP20140437T1 (el)
IL (1) IL221487A (el)
MX (1) MX2012009482A (el)
NZ (1) NZ602271A (el)
PL (1) PL2536722T3 (el)
PT (1) PT2536722E (el)
RS (1) RS53458B (el)
SA (1) SA111320200B1 (el)
SG (1) SG183329A1 (el)
SI (1) SI2536722T1 (el)
SM (1) SMT201400090B (el)
TW (1) TW201130838A (el)
WO (1) WO2011101806A1 (el)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214483B (zh) 2005-12-13 2014-12-17 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2，3-b]吡啶和吡咯并[2，3-b]嘧啶
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
KR102283091B1 (ko) 2010-03-10 2021-07-30 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US8889870B2 (en) 2012-03-12 2014-11-18 Allergan, Inc. Kinase inhibitors
US9388176B2 (en) 2012-03-12 2016-07-12 Allergan, Inc. Method of treating conditiions with kinase inhibitors
SG11201408238WA (en) 2012-06-13 2015-01-29 Incyte Corp Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EP2951590A1 (en) 2013-02-04 2015-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
AU2014275643B2 (en) * 2013-06-05 2018-08-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
EP3030227B1 (en) 2013-08-07 2020-04-08 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
PT3636649T (pt) 2014-01-24 2024-04-09 Turning Point Therapeutics Inc Diaril macrociclos como moduladores das proteínas quinases
MX2016013027A (es) 2014-04-04 2017-05-23 Del Mar Pharmaceuticals Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9321766B1 (en) 2014-10-06 2016-04-26 Allergan, Inc. Kinase inhibitors
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2017004342A1 (en) 2015-07-02 2017-01-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
MX2018000718A (es) 2015-07-21 2020-01-20 Turning Point Therapeutics Inc Macrociclos de diarilo quirales y usos de los mismos.
CN107459519A (zh) * 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN110612119A (zh) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018222917A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
JP7126084B2 (ja) 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
US11286264B2 (en) 2017-07-28 2022-03-29 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
PL3728271T3 (pl) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
JP2021512147A (ja) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Ｃａｒ ｔ細胞の使用方法
PE20211310A1 (es) 2018-01-30 2021-07-22 Incyte Corp Procedimiento para la elaboracion de un recipiente de vidrio de sosa-cal a partir de materiales formadores de vidrio 100% reciclados y un recipiente de vidrio elaborado a partir de dicho procedimiento
JP2021519775A (ja) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療
WO2019213506A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
CN109336868A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 吲哚类stat3抑制剂及其制备方法
CN109293641A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种芴类stat3抑制剂及其制备方法
CN109485643A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种芴酮类stat3抑制剂及制备方法与应用
CN109369627A (zh) * 2018-10-31 2019-02-22 南京先进生物材料与过程装备研究院有限公司 芴酮类stat3抑制剂晶型a及制备方法
CN109180657A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 Stat3抑制剂的制备方法
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4349472A (en) 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
PL344248A1 (en) * 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
ES2265452T3 (es) * 2000-12-21 2007-02-16 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
CA2542105C (en) * 2003-10-08 2011-08-02 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1981886B1 (en) 2006-01-31 2009-08-12 F.Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
WO2008077062A2 (en) 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8183245B2 (en) 2007-10-25 2012-05-22 Merck Sharp & Dohme Corp. Pyrazine substituted pyrrolopyridines as inhibitors of JAK and PDK1
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة

Also Published As

Publication number Publication date
PT2536722E (pt) 2014-05-26
WO2011101806A1 (en) 2011-08-25
US8440679B2 (en) 2013-05-14
US8962637B2 (en) 2015-02-24
JP2013519725A (ja) 2013-05-30
US20130143895A1 (en) 2013-06-06
DK2536722T3 (da) 2014-05-26
RS53458B (en) 2014-12-31
IL221487A (en) 2014-11-30
NZ602271A (en) 2013-09-27
AU2011216895A1 (en) 2012-09-27
SMT201400090B (it) 2014-09-08
ES2470190T3 (es) 2014-06-23
AU2011216895B2 (en) 2015-11-05
EA201290757A1 (ru) 2013-04-30
SI2536722T1 (sl) 2014-10-30
CA2789655A1 (en) 2011-08-25
MX2012009482A (es) 2012-11-29
SG183329A1 (en) 2012-09-27
HRP20140437T1 (hr) 2014-08-29
KR20120130294A (ko) 2012-11-30
BR112012020639A2 (pt) 2017-08-08
CU20120118A7 (es) 2012-10-15
PL2536722T3 (pl) 2014-11-28
US20130012518A1 (en) 2013-01-10
EP2536722A1 (en) 2012-12-26
SA111320200B1 (ar) 2014-02-16
AR089641A1 (es) 2014-09-10
CN102858770A (zh) 2013-01-02
TW201130838A (en) 2011-09-16
EP2536722B1 (en) 2014-04-16
HK1178897A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
CY1115420T1 (el) Δικυκλικες ενωσεις και οι χρησεις τους ως διπλοι αναστολεις c-src/jak
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
EA201491356A1 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
CY1123702T1 (el) Πυραζολο[1,5-αλφα]πυριμιδινες χρησιμες ως αναστολεις της κινασης atr για την αντιμετωπιση καρκινικων νοσων
CY1114092T1 (el) Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης
CY1117604T1 (el) Μια νεα ομαδα αναστολεων του μονοπατιου stat3 και αναστολεων του μονοπατιου καρκινικων βλαστοκυτταρων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1114539T1 (el) Η χρησιμοτητα των ιμιδαζοπυριδαζινοκαρβονιτριλιων ως αναστολεων κινασων
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
CY1118112T1 (el) Διυποκατεστημενες βενζοθειενυλ-πυρρολοτριαζινες και η χρηση τους ως αναστολεις κινασης υποδοχεα του αυξητικου παραγοντα των ινοβλαστων (fgfr)
CY1118004T1 (el) Αναστολεις cdk
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CY1116315T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
EA201201677A1 (ru) Производные гетероарилимидазолона в качестве ингибиторов jak
EA201200552A1 (ru) Производные пиримидина в качестве ингибиторов протеинтирозинкиназы 2
EA201490418A1 (ru) Новые макроциклические соединения в качестве ингибиторов фактора xia
EA201590284A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
UY31711A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización
CY1111789T1 (el) Ετεροκυκλικες ενωσεις
EA201270339A1 (ru) Замещенные производные ксантина
EA201270730A1 (ru) ИНГИБИТОРЫ КИНАЗЫ Cdc7 И ИХ ПРИМЕНЕНИЕ